MA-ONAPSIS
Onapsis , the leader in business-critical application cybersecurity and compliance, today announced the release of Onapsis Assess Baseline. In a world where business-critical applications are under attack every day, this new offering accelerates organizations’ abilities to kickstart their SAP vulnerability management programs by better aligning with the SAP Security Baseline.
The exponential growth of targeted ransomware and the increased threat of cyber warfare due to global conflict means that organizations must re-evaluate how they secure their most critical systems. Amid this evolving, more aggressive threat landscape , companies struggle to keep up with patching the growing number of vulnerabilities exploited by threat actors to gain access to their business-critical applications. Onapsis Assess Baseline empowers companies of any size to accelerate time-to-value by simplifying deployment with a new SaaS-based, zero-footprint model and focusing on a core, targeted set of critical vulnerabilities as first steps on their journey to ensure cybersecurity, compliance, and availability of their SAP applications. When organizations are ready to take on more, Onapsis Assess Baseline offers easy expansion to additional scope for vulnerability management as well as capabilities for continuous threat monitoring and application security testing.
Key Organizational Benefits with Onapsis Assess Baseline:
- Reduce Implementation Overhead with an Accelerated Deployment: Whether in their own cloud, on-premises, or through Onapsis’ SaaS platform, Assess Baseline offers quick deployment and implementation with zero footprint scanning.
- Accelerate Time-to-Value for SAP Vulnerability Management: Onapsis SaaS users can scan with Assess Baseline against the SAP-recommended security baseline requirements for an organization’s SAP systems within hours. The scans deliver powerful context around critical vulnerabilities, instructions on how to mitigate, and confidence that patches were applied, saving valuable resource time.
- Technology that Scales and Grows When You’re Ready: Deploy where you want. Scan across the entire SAP landscape. Start small and target the most critical systems first, get them aligned to a baseline, and then expand the security scope across the organization on your terms.
“Securing business-critical applications has always been challenging, but there’s a larger bullseye on the backs of organizations today - more than ever before - as sophisticated threat actors increasingly target Enterprise Resource Planning (ERP) systems,” said Mariano Nunez, CEO of Onapsis. “We have successfully helped the world’s largest and most sophisticated organizations integrate their business applications into their cybersecurity and compliance programs. Now, Assess Baseline makes it easy for customers who are getting started with their SAP application security programs to quickly and effectively jumpstart protecting the applications that power their businesses.”
The Onapsis Platform secures the critical SAP applications that keep the global economy running. The platform is purpose-built to deliver impactful vulnerability management, advanced threat detection, custom code inspection, and automated compliance that enables global organizations to accelerate their business and digital transformation initiatives. The Onapsis Platform is deeply informed by the latest threat intelligence and security guidance from the Onapsis Research Labs. This market-leading team has discovered more than 800 zero-day vulnerabilities and is responsible for multiple critical global CERT alerts.
“Today’s threat landscape requires a holistic approach to securing business-critical SAP applications such as ERP software,” said Steve Biskie, national ERP risk and automation services leader with RSM US LLP. “It is exciting to see Onapsis continuing to innovate its solutions to assist companies on their security maturity journey. The new Baseline license can help pave the way for more organizations to have an entry point into vulnerability management for SAP applications that could help keep their critical data and applications safe and compliant.”
Attending the SAP Sapphire conference? Visit the Onapsis booth to learn more: #PA219
To schedule a time to speak with an Onapsis expert while at Sapphire, please visit: https://onapsis.com/sapphire-22
About Onapsis
Onapsis protects the business-critical applications that run the global economy, from the core to the cloud. The company’s cybersecurity and compliance solution offering, The Onapsis Platform, uniquely delivers vulnerability management, threat detection and response, change assurance, and continuous compliance for business-critical applications from leading vendors such as SAP, Oracle, Salesforce, and other SaaS platforms.
Onapsis is headquartered in Boston, MA, with offices in Heidelberg, Germany and Buenos Aires, Argentina, and proudly serves more than 300 of the world’s leading brands, including 20% of the Fortune 100, 6 of the top 10 automotive companies, 5 of the top 10 chemical companies, 4 of the top 10 technology companies, and 3 of the top 10 oil and gas companies.
The Onapsis Platform is powered by the Onapsis Research Labs, the team responsible for the discovery and mitigation of more than 800 zero-day vulnerabilities in business-critical applications. The reach of our threat research and platform is broadened through leading consulting and audit firms such as Accenture, Deloitte, IBM, PwC, and KPMG — making Onapsis solutions the standard in helping organizations protect their cloud, hybrid, and on-premises business-critical information and processes. For more information, connect with us on Twitter or LinkedIn , or visit us at https://onapsis.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005214/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release
At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release
Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press release
300mm SiC Technology, Enabling Scalable Platforms for AI Infrastructure, AR/VR, and Advanced Power DevicesAnnouncement highlights:Strategic Technology Milestone – Wolfspeed has produced a single crystal 300mm (12-inch) silicon carbide wafer, representing a major advancement in the evolution of silicon carbide technology and a critical enabler for emerging applications. Technology leadership for Next-Gen Applications – Backed by one of the industry’s largest and most foundational silicon carbide IP portfolios, with over 2,300 issued and pending patents worldwide, Wolfspeed is accelerating the commercialization of 300mm technology to power next-generation platforms including AI infrastructure, augmented reality/virtual reality (AR/VR) and advanced power devices. Strengthening U.S. Semiconductor Leadership & Supply Chain Resilience –The company’s vertically integrated supply chain, from crystal growth to advanced packaging, supports national goals around compound semiconductor independenc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
